Cookies on this site

More effective diagnosis and treatments are needed to reduce the morbidity and mortality affecting malaria patients. Researchers at the Malaria Laboratory at MORU study the pathophysiology of the disease, and test new compound drugs for anti-malarial activity. In the context of growing artemisinin resistance, this research will have a global impact.

Kesinee Chotivanich: Malaria is one of the neglected diseases, and it's a disease of poor people. If you would like to reduce the morbidity or mortality of patients you need to treat them effectively, with effective diagnosis and treatment.

One of the key factors to eliminate malaria is to kill the parasites. To do that, you have to know where they are. Even in low levels or in asymptomatic cases you have to know where the parasites are in order to kill them. To prevent the transmission from people to people, we need to stop the transmission between the mosquito (the vector) and people.

So all this you need to know. Which drug will be very effective in all steps of malaria transmission. We are interested in the pathophysiology of malaria, in the factors that affect the severity of the disease. We try to see how we can protect, or help to decrease the chance to get severe malaria. Also the anti-malaria drug activity: we first screen and try to see any anti-malarial activities of new compounds, by screening to see if they help treat anti-malaria drug resistance. Because in this region (Thailand) we have a problem with multi drug resistance. That means we need new anti-malarial drugs or new treatment regimens urgently.

Q: Why does your line of research matter and why should we fund it?

KC: The hot topic is artemisinin resistance. Our group is the first to develop a new methodology to detect artemisinin-resistant parasites. We have a chance to look at new anti-malarial drugs to see if they can be used in the context of anti-malarial drug resistance in the future. To help them, to improve patient's care and to eliminate malaria, we need support. And the support should go to the people who have high capability to make high quality research and impact health policy. All the funding that goes to our group will help not only the people who have a malaria infection but will also help people everywhere.

Kesinee Chotivanich

Dr Kesinee Chotivanich heads the Malaria laboratory at MORU. This laboratory provides facilities and resources to researchers, students, and collaborators who are interested in tropical diseases, with the aim to improve patients' care. Areas of interest include the pathophysiology of malaria, host-parasite interaction, pharmacodynamics of antimalarial drugs, mechanism of antimalarial drug resistance, and development of diagnostic tools.

More podcasts related to Malaria

Francis Ndungu: Decoding natural immunity to malaria

Francis Ndungu studies malaria immunity using controlled human infection models to understand protective mechanisms in highly exposed populations. His research supports vaccine development and optimisation, including RTS,S and R21. By reducing malaria burden, especially among children and pregnant women, these tools also have the potential to accelerate economic development in endemic countries.

James Watson: Data driven definitions of severe malaria

James Watson studies severe malaria in African children, focusing on improving diagnostic accuracy. By analysing clinical data, he aims to distinguish malaria-related severe illness from other infections and estimate true mortality more reliably. His work supports faster diagnosis and treatment, ultimately reducing preventable child deaths in low-resource settings.

Philippe Guérin: Enabling data reuse to combat infectious diseases

IDDO is a data platform that facilitates the integration and analysis of individual patient data from diverse studies, uncovering new insights otherwise inaccessible. Through meticulous curation and merging of data, IDDO unearth crucial evidence, such as the impact of malaria treatment on malnourished children, a group usually excluded from trials. This comprehensive approach not only informs better treatment strategies but also identifies gaps in current knowledge, guiding future research directions and potentially transforming healthcare guidelines worldwide.

Marta Maia: Vector control to fight malaria

Malaria is mostly controlled through the use of bed nets and insecticides, but progress has stalled and we need new vector control interventions. Mosquitoes can be affected by endectocides carried in the blood of hosts. Clinical trials will determine whether ivermectin administered to human or cattle can be used to impact malaria transmission.

Isabella Oyier: Malaria and immunity

Understanding mutations in the malaria parasite gives us an insight how it escapes the immune system, as well as the mechanisms of drug resistance. This molecular work also helps find better candidates for malaria vaccines. In the long term, surveillance of markers of resistance informs national drug policy.

Melissa Kapulu: Malaria transmission and human infection studies

The efficacy of vaccine developed in naïve population (UK or US) often drops dramatically when used in endemic populations, where individuals are exposed to the vaccine disease target. The Human Malaria Infection Model looks at naturally acquired immunity and correlates of protection. Furthermore, scientists in affected areas build capacity and knowledge base, and integration of scientific thought and processes.

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.